The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of atezolizumab (anti-PD-L1) with carboplatin in patients with metastatic triple-negative breast cancer (mTNBC).
 
Eric Michael Lander
No Relationships to Disclose
 
Brian David Lehmann
No Relationships to Disclose
 
Payal D Shah
Stock and Other Ownership Interests - Amgen; Johnson & Johnson; Johnson & Johnson (I); Merck (I); Novartis (I); Novo Nordisk; Novo Nordisk (I); Pfizer (I)
Consulting or Advisory Role - Tmunity Therapeutics, Inc.
 
Elizabeth Claire Dees
Consulting or Advisory Role - G1 Therapeutics; Novartis (I); Strata Oncology
Research Funding - Bayer; Cerulean Pharma; Genentech/Roche; H3 Biomedicine; Lilly; Merck; Meryx Pharmaceuticals; Novartis; Pfizer
Travel, Accommodations, Expenses - G1 Therapeutics
 
Tarah Jean Ballinger
Honoraria - Novartis
Consulting or Advisory Role - Medscape
 
Paula Raffin Pohlmann
Leadership - Immunonet BioSciences
Stock and Other Ownership Interests - Immunonet BioSciences
Honoraria - ASCO; Dava Oncology
Consulting or Advisory Role - Caris Life Sciences; HERON; Immunonet BioSciences; Juniper Pharmaceuticals; OncoPlex Diagnostics; Personalized Cancer Therapy; Pfizer; Puma Biotechnology; Sirtex Medical
Speakers' Bureau - Genentech/Roche
Research Funding - Advanced Cancer Therapeutics (Inst); Caris Centers of Excellence (Inst); Caris Centers of Excellence (Inst); Cascadian Therapeutics (Inst); Fabre-Kramer (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Pfizer (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - United States Patent no. 8,486,413.; United States Patent no. 8,501,417; United States Patent no. 9,023,362; United States Patent no. 9,745,377
 
Cesar Augusto Santa-Maria
Consulting or Advisory Role - Athenex; Bristol-Myers Squibb; Genomic Health; Halozyme; Polyphor
Research Funding - Medimmune; Pfizer; Pfizer; Tesaro (Inst)
 
Yu Shyr
Consulting or Advisory Role - Aduro Biotech; GlaxoSmithKline; Janssen Research & Development; Novartis; Pfizer; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Royalty for TNBCType for Insight Genetics. TNBCType is a web-based subtyping tool TNBCtype for candidate TNBC samples using our gene expression meta data and classification method.
 
Ingrid A. Mayer
Consulting or Advisory Role - Abbvie; AstraZeneca; Genentech; GlaxoSmithKline; Immunomedics; Lilly; Macrogenics; Novartis; Pfizer; Puma Biotechnology; Seagen
Research Funding - Genentech (Inst); Novartis (Inst); Pfizer (Inst)
 
Ben Ho Park
Leadership - Loxo
Stock and Other Ownership Interests - Celcuity; Loxo
Honoraria - AstraZeneca
Consulting or Advisory Role - Casdin Capital; Celcuity; Foundation Medicine; H3 Biomedicine; Horizon Discovery; Jackson Laboratory for Genomic Medicine; Lilly; Loxo
Research Funding - Abbvie; Foundation Medicine; GE Healthcare; Pfizer
Patents, Royalties, Other Intellectual Property - Royalties paid through inventions at Johns Hopkins University by Horizon Discovery LTD
Travel, Accommodations, Expenses - Lilly; Loxo
(OPTIONAL) Uncompensated Relationships - Tempus
 
Jennifer A. Pietenpol
No Relationships to Disclose
 
Vandana G Abramson
Employment - HCA Healthcare (I)
Consulting or Advisory Role - Abbvie; Daiichi Sankyo; Eisai
Research Funding - Astellas Pharma; Genentech/Roche; Lilly